5:09 PM
 | 
Jul 29, 2013
 |  BC Extra  |  Top Story

Celgene receives option to acquire Acetylon

Celgene Corp. (NASDAQ:CELG) paid $100 million up front in exchange for an exclusive option to acquire Acetylon Pharmaceuticals Inc. (Boston, Mass.). If Celgene exercises its option, Acetylon will receive at least $500 million in cash up front, and Acetylon shareholders would be...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >